Zimmer Partners LP Sells 20,000 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Zimmer Partners LP reduced its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 5.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 348,700 shares of the company’s stock after selling 20,000 shares during the period. Zimmer Partners LP owned about 0.16% of Sana Biotechnology worth $1,451,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Stifel Financial Corp bought a new position in Sana Biotechnology in the 3rd quarter valued at approximately $43,000. EP Wealth Advisors LLC bought a new stake in shares of Sana Biotechnology in the third quarter worth $45,000. Blue Trust Inc. raised its position in Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after purchasing an additional 12,154 shares during the last quarter. Algert Global LLC acquired a new position in Sana Biotechnology during the 2nd quarter worth about $73,000. Finally, Cornercap Investment Counsel Inc. bought a new stake in shares of Sana Biotechnology in the 3rd quarter valued at about $67,000. 88.23% of the stock is owned by institutional investors.

Insider Transactions at Sana Biotechnology

In other news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 31.10% of the company’s stock.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $2.30 on Friday. The stock has a market capitalization of $513.52 million, a price-to-earnings ratio of -1.64 and a beta of 1.33. The stock’s 50 day moving average price is $3.35 and its two-hundred day moving average price is $4.92. Sana Biotechnology, Inc. has a 52-week low of $2.28 and a 52-week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SANA shares. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research note on Wednesday, November 27th. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.